U.S. Markets closed
  • S&P Futures

    3,749.75
    -7.00 (-0.19%)
     
  • Dow Futures

    29,949.00
    -33.00 (-0.11%)
     
  • Nasdaq Futures

    11,512.25
    -29.50 (-0.26%)
     
  • Russell 2000 Futures

    1,757.30
    -0.80 (-0.05%)
     
  • Crude Oil

    88.59
    +0.14 (+0.16%)
     
  • Gold

    1,720.70
    -0.10 (-0.01%)
     
  • Silver

    20.63
    -0.03 (-0.15%)
     
  • EUR/USD

    0.9796
    +0.0001 (+0.0098%)
     
  • 10-Yr Bond

    3.8260
    +0.0670 (+1.78%)
     
  • Vix

    30.52
    +1.97 (+6.90%)
     
  • GBP/USD

    1.1151
    -0.0017 (-0.1561%)
     
  • USD/JPY

    144.9250
    -0.1430 (-0.0986%)
     
  • BTC-USD

    19,986.79
    -297.82 (-1.47%)
     
  • CMC Crypto 200

    454.71
    -8.41 (-1.82%)
     
  • FTSE 100

    6,997.27
    -55.35 (-0.78%)
     
  • Nikkei 225

    27,041.19
    -270.11 (-0.99%)
     

Is Now An Opportune Moment To Examine Medpace Holdings, Inc. (NASDAQ:MEDP)?

·3 min read

While Medpace Holdings, Inc. (NASDAQ:MEDP) might not be the most widely known stock at the moment, it led the NASDAQGS gainers with a relatively large price hike in the past couple of weeks. With many analysts covering the mid-cap stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. However, what if the stock is still a bargain? Let’s examine Medpace Holdings’s valuation and outlook in more detail to determine if there’s still a bargain opportunity.

View our latest analysis for Medpace Holdings

Is Medpace Holdings Still Cheap?

Good news, investors! Medpace Holdings is still a bargain right now. My valuation model shows that the intrinsic value for the stock is $218.79, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. Although, there may be another chance to buy again in the future. This is because Medpace Holdings’s beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity.

Can we expect growth from Medpace Holdings?

earnings-and-revenue-growth
earnings-and-revenue-growth

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. With profit expected to grow by 22% over the next couple of years, the future seems bright for Medpace Holdings. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.

What This Means For You

Are you a shareholder? Since MEDP is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With a positive outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on MEDP for a while, now might be the time to make a leap. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy MEDP. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed investment decision.

If you'd like to know more about Medpace Holdings as a business, it's important to be aware of any risks it's facing. While conducting our analysis, we found that Medpace Holdings has 1 warning sign and it would be unwise to ignore this.

If you are no longer interested in Medpace Holdings, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here